QIAGEN has announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QIAreach® SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results.
The rapid portable test can detect SARS-CoV-2 antigen in people with active infections in 2 to 15 minutes and can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation. Clinical studies have shown the test to have a sensitivity of at least 80% and a specificity of 98.0%.
{iframe}https://www.selectscience.net/industry-news/qiagen-receives-fda-authorization-for-rapid-portable-test-that-can-analyze-over-30-samples-per-hour-for-sars-cov-2-antigen/?artID=55492{/iframe}